Document is current
Any future updates will be listed below
-
Authors
Valero-Muñoz, María
Saw, Eng Leng
Pimentel, David R.
Gower, Adam C. https://orcid.org/0000-0002-6122-7511
Srinivasa, Suman
Zanni, Markella V.
Toribio, Mabel
Grinspoon, Steven K.
Sam, Flora https://orcid.org/0000-0001-8442-9362
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (RO1HL145985)
- License Information
-
More Information
Article History
Received: 18 March 2025
Accepted: 18 December 2025
First Online: 31 December 2025
Competing interests
: F.S. is a full-time employee of Eli Lilly and Co, Indianapolis. None of the work was funded nor supported by Eli Lilly and Co. F.S. has no other conflicts to disclose regarding the work in this manuscript. M.V.Z. is Principal Investigator on an Investigator-initiated research grant from Gilead to her institution (MGH), unrelated to the work in this manuscript. S.K.G. has received research support from Kowa Pharmaceuticals, Viiv and Gilead unrelated to this manuscript. He serves on the Advisory Boards of Exavir Therapeutics and Marathon Asset Management unrelated to this manuscript. The remaining authors have no conflicts of interest to declare.
